BURLINGTON, Mass., Nov. 13,
2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
today announced that B Medical Systems S.à r.l ("B Medical") and
The Ministry of Public Health, Hygiene and Prevention of the
Democratic Republic of the Congo
(DRC) (the "Ministry") have entered into a Memorandum of
Understanding ("MOU") for B Medical to deliver a complete solution
suitable for the storage and transport of vaccines with real-time
traceability, as well as the delivery of Toyota vehicles, which
have been customized with B Medical cold chain solutions, and other
complementary equipment under a new €100 million National
Vaccination Service project in the DRC. More than 50% of the
project value is expected to be recognized as B Medical revenue for
Azenta.
The Ministry is responsible for developing and implementing
health policies, plans and strategies in the DRC and has selected B
Medical as its cold chain solutions partner in its new National
Vaccination Service ("SNAV"). SNAV will address the entire health
structure in the DRC all the way down to the local health area
level to reach the entire population.
"Over the past four decades, B Medical has demonstrated a clear
ability to quickly and effectively address the urgent health needs
of the DRC. We look forward to continuing and strengthening our
partnership with B Medical to support the well-being of the
Congolese population," stated Dr. Samuel Roger Kamba, Minister
of Public Health, Hygiene and Prevention of the DRC.
"We are proud to be selected as the key cold chain solutions
provider for this significant humanitarian initiative in the DRC,"
stated Luc Provost, VP, CEO B
Medical. "Our manufacturing operations in Luxembourg are ready to step-up to meet the
needs of this order, which is the largest ever for our business,
and we expect to deliver the shipments to the DRC in fiscal
2024."
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington, MA, with operations
in North America, Europe and Asia. For more
information, please visit www.azenta.com.
INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Azenta's financial and business results and the forward-looking
statements in this release to differ materially from our
expectations. These statements are based on the facts known to
management at the time they are made. Forward-looking statements
include but are not limited to statements about: the memorandum of
understanding (MOU) with The Ministry of Public Health, Hygiene and
Prevention of the Democratic Republic of
the Congo (the "Ministry"), the timing and/or amount of
revenue to the Company from the MOU, and the potential benefits of
any future partnership with the Ministry. Factors that could cause
results to differ from our expectations include the following: our
ability to reduce costs effectively, the impact of the COVID-19
global pandemic on the markets we serve, including our supply
chain, and on the global economy generally; the volatility of the
life sciences markets Azenta serves; our possible inability to
meet demand for our products due to difficulties in obtaining
components and materials from our suppliers in required quantities
and of required quality; the inability of customers to make
payments to us when due; price competition; disputes concerning
intellectual property; uncertainties in global political and
economic conditions; our ability to successfully invest the cash
proceeds from the sale of our semiconductor automation business;
and other factors and other risks, including those that we have
described in our filings with the Securities and Exchange
Commission, including but not limited to our Annual Report on Form
10-K, Current Reports on Form 8-K and our Quarterly Reports on Form
10-Q. As a result, we can provide no assurance that future results
will not be materially different from the forward-looking
statements in this release. Azenta expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any such statement to reflect any change in our
expectations or any change in events, conditions, or circumstances
on which any such statement is based. Azenta undertakes no
obligation to update the information contained in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-agreement-between-b-medical-and-the-ministry-of-public-health-hygiene-and-prevention-of-the-democratic-republic-of-the-congo-for-a-significant-national-universal-health-project-301986546.html
SOURCE Azenta